Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O00267
UPID:
SPT5H_HUMAN
Alternative names:
DRB sensitivity-inducing factor 160 kDa subunit; DRB sensitivity-inducing factor large subunit; Tat-cotransactivator 1 protein
Alternative UPACC:
O00267; O43279; Q59G52; Q99639
Background:
Transcription elongation factor SPT5, also known as DRB sensitivity-inducing factor 160 kDa subunit, plays a pivotal role in mRNA processing and transcription elongation by RNA polymerase II. It is a component of the DSIF complex, enhancing mRNA capping and transcriptional pausing, which is crucial for the assembly of an elongation competent RNA polymerase II complex. SPT5's interaction with the HIV-1 nuclear transcriptional activator, Tat, underscores its importance in transcriptional regulation.
Therapeutic significance:
Understanding the role of Transcription elongation factor SPT5 could open doors to potential therapeutic strategies. Its involvement in transcriptional regulation and mRNA processing highlights its potential as a target for therapeutic intervention in diseases where these processes are dysregulated.